Detalhe da pesquisa
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
2.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564045
3.
Chromothripsis as a pathogenic driver of multiple myeloma.
Semin Cell Dev Biol
; 123: 115-123, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958284
4.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654611
5.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541152
6.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438407
7.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
8.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656799
9.
Toward personalized treatment in multiple myeloma based on molecular characteristics.
Blood
; 133(7): 660-675, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587529
10.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499244
11.
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Eur J Haematol
; 106(2): 230-240, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33107092
12.
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage.
J Immunol
; 212(8): 1392, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416013
13.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769076
14.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373884
15.
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Blood
; 132(1): 59-66, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29784643
16.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood
; 132(6): 587-597, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29884741
17.
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma.
Haematologica
; 105(4): 1055-1066, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221783
18.
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.
Hum Genomics
; 13(1): 37, 2019 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31429796
19.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559051
20.
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Br J Haematol
; 184(4): 578-593, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408155